相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li et al.
GASTROENTEROLOGY (2019)
The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention
Zhenqiu Liu et al.
JOURNAL OF HEPATOLOGY (2019)
Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
Magnus Rizell et al.
FRONTIERS IN ONCOLOGY (2019)
Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis
Javier Fernandez et al.
GUT (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Expression and clinical significance of PD-1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD-1 monoclonal antibody
Ziwei Li et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy
N. Kumar et al.
HLA (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Systemic treatments for metastatic cutaneous melanoma
Sandro Pasquali et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review
Xiu-Rong Cai et al.
ONCOTARGET (2017)
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
Tomi Akinyemiju et al.
JAMA ONCOLOGY (2017)
Management of people with early-or very early-stage hepatocellular carcinoma: an attempted networkmetaanalysis
Avik Majumdar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+hepatocellular carcinoma (r/r GPC3+HCC).
Bo Zhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally et al.
CELL (2017)
Adoptive T Cell Therapy: An Overview of Obstacles and Opportunities
Erez Nissim Baruch et al.
CANCER (2017)
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
352PDA phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
S. Jiang et al.
ANNALS OF ONCOLOGY (2016)
The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment
Cristina Margini et al.
LIVER INTERNATIONAL (2016)
Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
Longhao Sun et al.
TUMOR BIOLOGY (2016)
Nonalcoholic fatty liver disease and hepatocellular carcinoma
Heinz Zoller et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials
Zhipeng Sun et al.
BIOSCIENCE TRENDS (2016)
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Takahiro Kamiya et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Targeting alpha fetoprotein with TCR engineered T cells in HCC
Andrew Gerry et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Joon Hyeok Lee et al.
GASTROENTEROLOGY (2015)
The yin and yang of evasion and immune activation in HCC
Oxana V. Makarova-Rusher et al.
JOURNAL OF HEPATOLOGY (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma
Yanmei Han et al.
HEPATOLOGY (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions
Tai Hato et al.
HEPATOLOGY (2014)
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Agustin Albillos et al.
JOURNAL OF HEPATOLOGY (2014)
Human serum albumin, systemic inflammation, and cirrhosis
Vicente Arroyo et al.
JOURNAL OF HEPATOLOGY (2014)
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
Jessica Dyson et al.
JOURNAL OF HEPATOLOGY (2014)
Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3- regulatory T cell suppresses T cell response via membrane-bound TGF-β1
Yanmei Han et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Ana C. Anderson
CANCER IMMUNOLOGY RESEARCH (2014)
Hepatocellular Carcinoma from an Immunologic Perspective
Tim F. Greten et al.
CLINICAL CANCER RESEARCH (2013)
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Virginia Hernandez-Gea et al.
GASTROENTEROLOGY (2013)
Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions
Yan Wu et al.
HEPATOLOGY (2013)
Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients
Fu-Jun Li et al.
IMMUNOLOGY LETTERS (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes
Daisuke Nobuoka et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence
Hiroteru Kamimura et al.
JOURNAL OF HEPATOLOGY (2012)
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Uzma Asghar et al.
JOURNAL OF HEPATOLOGY (2012)
Management of bacterial infections in cirrhosis
Javier Fernández et al.
JOURNAL OF HEPATOLOGY (2012)
Inflammatory Immune Responses in Tumor Microenvironment and Metastasis of Hepatocellular Carcinoma
Lun-Xiu Qin
CANCER MICROENVIRONMENT (2012)
Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets
Tamara Severi et al.
ACTA PHARMACOLOGICA SINICA (2010)
Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Cell-mediated immune responses to α-fetoprotein and other antigens in hepatocellular carcinoma
Shahriar Behboudi et al.
LIVER INTERNATIONAL (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Antigen-presenting cell function in the tolerogenic liver environment
Angus W. Thomson et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
Hirofumi Shirakawa et al.
CANCER SCIENCE (2009)
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma
Hui Dong et al.
DIGESTIVE AND LIVER DISEASE (2009)
Natural Killer Cell Functional Dichotomy in Chronic Hepatitis B and Chronic Hepatitis C Virus Infections
Barbara Oliviero et al.
GASTROENTEROLOGY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Mei-Hwei Chang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors Reassessment of Risk Factors for Tumor Recurrence
Marco Vivarelli et al.
ANNALS OF SURGERY (2008)
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
Karin Gustafsson et al.
CANCER RESEARCH (2008)
Starring stellate cells in liver immunology
Florian Winau et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells
Bastian Hoechst et al.
GASTROENTEROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Liver: An organ with predominant innate immunity
Bin Gao et al.
HEPATOLOGY (2008)
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
Junliang Fu et al.
GASTROENTEROLOGY (2007)
The liver as an immunological organ
V Racanelli et al.
HEPATOLOGY (2006)
Early and late recurrence after liver resection for hepatocellular carcinoma - Prognostic and therapeutic implications
N Portolani et al.
ANNALS OF SURGERY (2006)
Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses
A Zerbini et al.
CANCER RESEARCH (2006)
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
G Fattovich et al.
GASTROENTEROLOGY (2004)
Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo
FS Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Weaning of immunosuppression in living donor liver transplant recipients
M Takatsuki et al.
TRANSPLANTATION (2001)
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
ZW Zhu et al.
GUT (2001)
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
T Takayama et al.
LANCET (2000)
分享论文
